Catalyst Pharmaceuticals (CPRX)
(Real Time Quote from BATS)
$21.18 USD
-0.28 (-1.31%)
Updated Dec 20, 2024 11:12 AM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
CPRX 21.18 -0.28(-1.31%)
Will CPRX be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CPRX
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
Other News for CPRX
PepGen stock down 22% on FDA clinical hold (update)
PepGen stock craters 35% on FDA clinical hold
Catalyst Pharmaceuticals Inc (CPRX) to Present at J.P. Morgan Healthcare Conference
Catalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable Future
JW Asset Management, LLC Reduces Stake in Establishment Labs Holdings Inc